Insider Buys Additional US$234k In Biodesix Stock
Insider Buys Additional US$234k In Biodesix Stock
Potential Biodesix, Inc. (NASDAQ:BDSX) shareholders may wish to note that the Independent Director, Jack Schuler, recently bought US$234k worth of stock, paying US$1.17 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
潛在的Biodesix, Inc.(納斯達克:BDSX)股東可能會注意到,獨立董事Jack Schuler最近以每股1.17美元的價格購買了價值23.4萬美元的股票。 然而,這僅增加了少量的參股金融,而且在絕對值上也不是一筆巨大的購買。
Biodesix Insider Transactions Over The Last Year
過去一年Biodesix內部交易
Notably, that recent purchase by Jack Schuler is the biggest insider purchase of Biodesix shares that we've seen in the last year. That implies that an insider found the current price of US$1.28 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.
值得注意的是,Jack Schuler的這筆近期購買是我們在過去一年中看到的Biodesix股票的最大內部人士購買。這意味着某位內部人士認爲當前每股1.28美元的價格具有吸引力。當然,他們可能會改變主意。但這表明他們是看好的。雖然我們總是喜歡看到內部人士的購買,但如果購買是在更低的價格時進行的,那就意義不大,因爲他們看到的機會可能已經過去。在這種情況下,我們很高興地報告,內部人士的購買是以接近當前價格進行的。
Biodesix insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Biodesix的內部人士在過去一年中可能購買了股票,但他們沒有賣出任何股票。下面的圖表顯示了過去一年內的內部交易(由公司和個人進行)。如果您想知道具體是誰賣了,賣了多少錢,以及何時賣出的,只需點擊下面的圖表!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
總有很多股票是內幕人士在買入。如果您喜歡投資知名度較低的公司,可以查看這個免費的公司名單。(提示:內幕人士一直在買入它們)。
Insider Ownership Of Biodesix
Biodesix 內部所有權
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Biodesix insiders own 47% of the company, currently worth about US$88m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
我喜歡查看公司內部人士持有多少股份,以幫助我了解他們與內部人士的利益一致程度。內部人士的高持股比例通常使公司領導層更加關注股東的利益。Biodesix 的內部人士擁有公司 47% 的股份,目前根據最近的股價,其價值約爲 8800萬美元。我喜歡看到這種水平的內部股權,因爲這增加了管理層考慮股東最佳利益的可能性。
So What Do The Biodesix Insider Transactions Indicate?
那麼 Biodesix 內部交易表明什麼?
The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Biodesix. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 2 warning signs for Biodesix (1 is a bit unpleasant!) that we believe deserve your full attention.
最近的內部人士購買讓人感到振奮。而長期的內部交易也讓我們充滿信心。但另一方面,公司在過去一年裏虧損,這讓我們有些謹慎。結合較高的內部所有權,這一分析表明內部人士對 Biodesix 的前景非常看好。這正是我想看到的!因此,雖然了解內部人士的買賣行爲很有幫助,但了解特定公司面臨的風險也同樣重要。當我們進行研究時,發現了 2 個 Biodesix 的警告信號(其中一個有點不愉快!),我們認爲這些信號值得你充分關注。
Of course Biodesix may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Biodesix 可能並不是最好的買入股票。因此你可能希望查看這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。